How Genentech Purifies Therapeutic Antibodies for Cancer Treatment

A method for refining mixtures of anti-HER2 antibodies to ensure that harmful acidic variants remain below 25 percent of the total composition.

What it covers

This patent describes a process for purifying therapeutic proteins, specifically anti-HER2 antibodies, using ion exchange chromatography. The core mechanism involves adjusting the conductivity and pH levels of buffer solutions to separate the desired antibody from unwanted acidic variants. By carefully controlling these chemical conditions, the process ensures that the final mixture contains less than 25 percent of these acidic byproducts, which is critical for maintaining the safety and efficacy of the drug.

What it doesn't cover

• —Does not cover general protein purification methods that do not specifically target anti-HER2 antibodies.
• —Does not cover purification techniques that rely solely on size-exclusion chromatography rather than ion exchange.
• —Does not cover compositions where the acidic variant concentration exceeds the 25 percent threshold.

The clever bit

The innovation lies in using precise conductivity and pH gradients to resolve subtle structural differences between a therapeutic antibody and its acidic variants, which are often nearly identical in size.

Why it matters

This patent is foundational for the production of monoclonal antibody therapies like Herceptin. By establishing strict purity standards for these complex biological molecules, it helped define the manufacturing quality control processes now standard in the biopharmaceutical industry.

Real-world examples

• 1.Herceptin (trastuzumab) manufacturing processes
• 2.Monoclonal antibody production lines
• 3.Biopharmaceutical quality control protocols